Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
about
Management of faecal incontinence and constipation in adults with central neurological diseasesManagement of faecal incontinence and constipation in adults with central neurological diseasesChronic constipation: current treatment optionsConsensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment)Patient considerations in the management of chronic constipation: focus on prucaloprideGuidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised EditionRecent Updates on the Treatment of ConstipationPractical treatments for constipation in KoreaLinaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adultsEmerging therapies for patients with symptoms of opioid-induced bowel dysfunctionTreatment for constipation: new and old pharmacological strategiesNovel therapies for constipationPrucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis.Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled TrialsPersistent constipation and abdominal adverse events with newer treatments for constipation.Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Understanding and treating refractory constipation.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationEfficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysisConstipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation.Systematic review of abdominal surgery for chronic idiopathic constipation.Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Review article: new receptor targets for medical therapy in irritable bowel syndromeEffect of electroacupuncture versus prucalopride for severe chronic constipation: protocol of a multi-centre, non-inferiority, randomised controlled trial.Prucalopride-associated acute tubular necrosis.Prucalopride for constipation.Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipationFermented milk containing Lactobacillus casei strain Shirota reduces incidence of hard or lumpy stools in healthy population.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersIrritable bowel syndrome: a clinical reviewRandomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 studyAmerican Gastroenterological Association technical review on constipation.Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Current management strategies and therapeutic targets in chronic constipation.Effect of prucalopride on symptoms of chronic constipation.Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipationRole of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.
P2860
Q24201142-AA419F91-A26C-48E1-B4C8-8A3F1C98124AQ24201722-9827826F-7701-414A-9BA6-9ECFB0355AF8Q24632528-3A4F7FE5-CDEE-43B6-A2E0-DE8940AC6805Q24633140-63809930-45EE-4F21-B90C-74B55176F295Q26741304-856D92CE-82D1-4974-B884-DBDEA69C632BQ26745952-20805453-777D-4AE2-B5A0-34D43D962358Q26820242-D83AD389-28A1-4C4C-91D4-25D3D5C6DF94Q26994785-A8B53F83-28FC-427D-A2B8-C59557133B61Q27010449-78EECBE1-47BE-41F1-B483-6A7898B5D887Q27010907-13CE113C-C671-49AE-9437-BE8E8E3284BFQ27027346-D4A8F872-A07B-462E-8C89-87E3F7F7ACECQ27027873-A58A471A-8C3A-444C-8E6E-4659842D22EBQ33461315-E0FAD6DD-2A6B-4D0A-A78D-BD8E10CE8157Q33467828-5B26FAB4-84E0-4986-BE60-D697CAE8D79CQ33468562-E20C2D0D-189A-49D9-AEC0-480BF7CDBB57Q33586854-94FF8CDE-6762-412F-9ECA-98DE8F85A45AQ33621273-37A2A07A-B7C7-4C53-849C-0E680C0A41E6Q33695487-9B1A2D04-194E-4536-B37D-CD452E2338D6Q33695505-14B9BEE1-15BD-4FF0-818B-0047678C85F8Q33695627-30CB8892-7C1B-404F-BF42-BE610EB9425BQ33726080-AE64F1A3-6EFD-4F41-AF15-DFF99E3827AEQ33854983-68592B49-66D6-4CBD-85CD-D0C7A436D9F0Q33958710-96051B42-F7DB-486B-AD4E-856123259E0FQ33959307-EE04E3FB-CAE5-427F-A879-EB6776A2801DQ33984572-C32B30AB-510E-411A-A385-DF457D9C5241Q34047629-BF0E4FB8-0828-4BF4-8CB4-EB43FC33252AQ34094831-58D9C808-6437-439C-97B7-3961B95755A1Q34146166-F26AFB6B-95F3-44DB-98CE-D4D6194C841BQ34164734-23A97C65-3653-4531-85EE-D4CB43E63358Q34166903-39DA36CB-95BB-4529-8A9D-B91EBD779E7CQ34168517-68887B4E-031B-4189-AF4C-28EA28B6A5B9Q34230555-9DF266F0-8B9D-47E5-BF35-09BA98CB898BQ34319119-0D3B7FC3-C4D4-47F5-9F4B-511B31AECB21Q34377144-83BE7A9D-CE0A-4D4B-A9DD-7377686F6553Q34409219-3ECC889C-4527-48CF-A600-F365E027A805Q34522966-A731F1BF-DC58-47F5-9356-0A6D45254387Q34565704-CDC135BF-9CE2-4B96-9704-15303D7BCF9EQ34806109-57B1F3E5-3577-4299-96C2-A796CB4B941BQ35018425-10F3C93E-AF97-482D-B9B5-E147647DA4EAQ35026383-B9916545-8388-4DC3-B9E1-AD8E891AB1A0
P2860
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@ast
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@en
Prucalopride
@nl
type
label
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@ast
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@en
Prucalopride
@nl
prefLabel
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@ast
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@en
Prucalopride
@nl
P2093
P356
P1433
P1476
Prucalopride (Resolor) in the ...... s dissatisfied with laxatives.
@en
P2093
L Vandeplassche
M van Outryve
R Kerstens
P304
P356
10.1136/GUT.2008.162404
P407
P577
2008-11-05T00:00:00Z